News

Shares of Organogenesis (NASDAQ: ORGO) were up 15.4% Wednesday afternoon after being up as much as 21.2% Wednesday morning. The healthcare company sells advanced wound care products for surgical and

Shares of Sarepta Therapeutics (NASDAQ: SRPT), which focuses on genetic treatments for rare diseases, were down 11.5% Wednesday afternoon after the Food and Drug Administration (FDA) pushed back its

Shares of the clinical-stage drugmaker Madrigal Pharmaceuticals (NASDAQ: MDGL) were up by 6.2% on elevated volume as of 12:16 p.m. ET Wednesday. The biotech appears to be benefiting from two key

Shares of Agilent Technologies (NYSE: A) were sinking 7.9% lower as of 11:34 a.m. ET on Wednesday. The decline came after the life sciences company announced its fiscal 2023 second-quarter results

There are reasons to be wary of the stock market right now. Chief among them is the fact that the economy continues to be somewhat uncertain, making it difficult to predict how things will develop

It's been tough to be an investor of late. Stocks are dishing out plenty of drama (and volatility) this year, making it uncomfortable to stick with them.

If your time frame truly is "forever,"

It's been tough to be an investor of late. Stocks are dishing out plenty of drama (and volatility) this year, making it uncomfortable to stick with them.

If your time frame truly is "forever,"

Medtronic (NYSE: MDT) is on a roll. Its shares have soared close to 15% year to date, easily outperforming the S&P 500.

But is Medtronic a stock to consider buying right now? Here are the bull and

Healthcare stocks make great additions to your portfolio at any time. You generally can count on the biggest players for a certain stability in earnings. That's because, in good times and in bad

The Federal Trade Commission (FTC) has been taking a much more adversarial approach to mergers and acquisitions lately. For instance, it recently said it plans to block the pending deal between

The Federal Trade Commission (FTC) has been taking a much more adversarial approach to mergers and acquisitions lately. For instance, it recently said it plans to block the pending deal between

The Federal Trade Commission (FTC) has been taking a much more adversarial approach to mergers and acquisitions lately. For instance, it recently said it plans to block the pending deal between

Shares of Integra LifeSciences (NASDAQ: IART) were crashing on Tuesday, with the stock falling 20.7% as of 3:39 p.m. ET. The steep decline came after the company revealed in a regulatory filing that

Shares of the Danish pharma giant Novo Nordisk (NYSE: NVO) were down by 3.4% on elevated volume as of 1:14 p.m. ET Tuesday afternoon. The drugmaker's shares are falling in response to the strong

Shares of the Danish pharma giant Novo Nordisk (NYSE: NVO) were down by 3.4% on elevated volume as of 1:14 p.m. ET Tuesday afternoon. The drugmaker's shares are falling in response to the strong

Shares of Akebia Therapeutics (NASDAQ: AKBA) were up more than 10% Tuesday after rising to as high as 13.1% in early trading. The biopharmaceutical company, which specializes in therapies to fight

Given the market volatility over the past few years, some investors are questioning whether they should still be putting their hard-earned money into the stock market. There is substantial economic

Given the market volatility over the past few years, some investors are questioning whether they should still be putting their hard-earned money into the stock market. There is substantial economic

Investors flocked to Pfizer (NYSE: PFE) stock on Monday following some highly encouraging news about one of the company's pipeline drugs. The holy grail of pharmaceutical companies and biotechs is

Investors flocked to Pfizer (NYSE: PFE) stock on Monday following some highly encouraging news about one of the company's pipeline drugs. The holy grail of pharmaceutical companies and biotechs is

On May 16, Pfizer (NYSE: PFE) announced that it was going to take out $31 billion in fresh debt to pay for its purchase of Seagen (NASDAQ: SGEN), an oncology drug developer. In total, it'll pay $43

On May 16, Pfizer (NYSE: PFE) announced that it was going to take out $31 billion in fresh debt to pay for its purchase of Seagen (NASDAQ: SGEN), an oncology drug developer. In total, it'll pay $43